Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.
Open Access
- 1 May 1992
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 89 (5) , 1382-1387
- https://doi.org/10.1172/jci115726
Abstract
Factor VIII East Hartford (FVIII-EH) procoagulant activity is reduced because the substitution of cysteine for arginine 1689 abolishes an essential Factor VIII light chain thrombin cleavage site. Incubation of FVIII-EH plasma with penicillamine or DTT causes a five- to sixfold increase in FVIII-EH VIII:C, at 80 and 1 mM, respectively. While there is no FVIII-EH light chain cleavage when thrombin is added in the presence of penicillamine or DTT, these reducing agents disrupt the FVIII-vWf complex. For example, the addition of 5 mM DTT to normal or FVIII-EH plasma causes a 50% reduction in Factor VIII binding to vWf. These observations suggested that DTT increases FVIII-EH VIII:C by partial dissociation of FVIII-EH from vWf. This was verified by showing that vWf-free FVIII-EH had VIII:C activity of 21 U/dl, while the starting plasma level was 2.5 U/dl. Removal of other FVIII-EH plasma proteins by agarose gel filtration had no effect on VIII:C activity. The demonstration that this mutant Factor VIII has cofactor function when separated from vWf indicates that the dissociation of Factor VIII from vWf is an essential effect of Factor VIII light chain cleavage at arginine-1689.Keywords
This publication has 32 references indexed in Scilit:
- CHARACTERIZATION OF A THROMBIN CLEAVAGE SITE MUTATION (ARG 1689 TO CYS) IN THE FACTOR-VIII GENE OF 2 UNRELATED PATIENTS WITH CROSS-REACTING MATERIAL-POSITIVE HEMOPHILIA-A1990
- Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.Proceedings of the National Academy of Sciences, 1989
- Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine).Proceedings of the National Academy of Sciences, 1989
- Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA TechnologyThrombosis and Haemostasis, 1989
- Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodiesBiochemistry, 1985
- Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.Journal of Clinical Investigation, 1985
- Immunoradiometric measurement of the factor VIII procoagulant antigen.Journal of Clinical Investigation, 1978
- Disulfide Bonds and the Quaternary Structure of Factor VIII/von Willebrand FactorJournal of Clinical Investigation, 1978
- ACTIVATION OF FACTOR-X BY FACTOR-IXA AND FACTOR-VIII SPECIFIC ASSAY FOR FACTOR-IXA IN PRESENCE OF THROMBIN-ACTIVATED FACTOR-VIII1978
- Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.Journal of Clinical Investigation, 1975